Thymalin is a polypeptide extract from calf or porcine thymus glands, used primarily in Eastern European clinical practice to restore immune function in people with weakened cellular immunity.
What it does
Thymalin is a mixture of short polypeptides (chains of amino acids) isolated from thymus tissue — the gland responsible for training T-lymphocytes, the white blood cells that coordinate the body's immune response. The core idea is that these peptides mimic signals the thymus normally sends to immature immune cells, pushing them to differentiate (mature into functional subtypes) and deploy correctly.
Specifically, Thymalin is reported to raise counts of CD4+ T-helper cells and CD8+ cytotoxic T-cells, and to normalize the ratio between T-helpers and T-suppressors (the cells that dial the immune response down). In secondary immunodeficiency — immune weakness caused by illness, surgery, radiation, or aging rather than a genetic defect — those ratios often become skewed. Thymalin appears to nudge them back toward normal.
Researchers in the Khavinson peptide program in Russia have also proposed epigenetic effects — meaning Thymalin may influence which thymus-related genes are switched on or off — though this line of evidence is early and not yet independently replicated in Western literature.
What the evidence shows
Immune restoration in secondary immunodeficiency Mostly clinical case series and institutional reports from Eastern Europe; no randomized controlled trials available in indexed English-language literature
The bulk of Thymalin's clinical record comes from Soviet and Russian medical practice spanning the 1980s through 2000s, where it was used in post-surgical recovery, oncology support, and age-related immune decline. Institutional reports describe improvements in T-cell counts and patient outcomes, but these studies are largely unavailable in peer-reviewed, indexed English journals, and no citations could be verified for this monograph. That is an honest limitation: the mechanism is biologically plausible and the clinical tradition is extensive, but Western-standard evidence — randomized trials, blinded controls, independent replication — is essentially absent.
Aging and thymic involution Theoretical and anecdotal; no controlled human trial data available
The thymus shrinks and loses function with age (a process called thymic involution), which correlates with declining T-cell diversity in older adults. Thymalin has been proposed as a way to partially compensate for this decline. The biological rationale is reasonable, but no verified controlled trials exist to confirm a meaningful clinical effect in this population.
How it's used
In studies and self-reported clinical protocols, Thymalin is administered by intramuscular (IM) injection — not orally, as digestive enzymes would break down the peptide fractions before absorption. Reported doses range from 5 mg daily for mild immune support to 10 mg daily for moderate immunodeficiency, typically run as a 5–10 day course. In severe immunodeficiency settings, doses up to 20 mg daily have been reported. Timing within the day appears to be flexible. The half-life is approximately 30 minutes, so the effect is thought to be signaling-driven rather than dependent on sustained plasma levels. Courses are sometimes repeated seasonally or after immune-stressing events such as surgery or illness.
Side effects and safety
Reported side effects are generally mild: injection site reactions (redness, soreness), transient fatigue, and occasional headache. Allergic reactions are uncommon but documented, and anaphylaxis — a severe, systemic allergic response — is listed as a rare but serious risk, which is not surprising given that Thymalin is a heterologous (animal-derived) protein extract. Absolute contraindications are pregnancy and known hypersensitivity to the preparation. Relative caution is advised in active severe autoimmune flares, since stimulating T-cell activity could theoretically worsen autoimmune conditions. Long-term safety data in humans is essentially unavailable in indexed literature, and the absence of standardized manufacturing quality controls across suppliers is a real and unresolved concern.
Bottom line
Thymalin has a decades-long clinical tradition in Eastern European medicine and a plausible mechanism for restoring T-cell function, but its evidence base does not meet current Western standards — no randomized controlled trials are available in indexed literature, and no citations could be verified for this monograph. It may be of interest to people researching immune restoration after significant illness or surgery, but the lack of rigorous trial data means the benefit-risk calculation cannot be made with confidence.